Half-year report · Q2
177A.TEDINET S100UQDH
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks11 of 11 passed
Key figures · 29
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥6.6bn | at 2024-03-31 | Cons. | Assets |
| Total liabilities | ¥3.2bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Cash and deposits | ¥3.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥824m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥577m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.43 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 13
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 351
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)小 林 雅 彦 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)筑 紫 徹 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | CurrentYTDDuration | 2507586000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 4770096000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 416879000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 635601000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 277196000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 384978000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 340686000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 403698000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 5279427000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 3342393000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 8515137000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 6589322000 | JPY |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 55.70 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 92.43 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.620 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.507 | |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 518146000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 823681000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -466696000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -577354000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | 1485818000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -1348000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 3306780000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 1726936000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5111600 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5111600 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 5111600 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 5111600 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 2209500 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.4323 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 416500 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0815 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 270000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0528 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 165351 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0323 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 154600 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0302 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 140000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0274 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 120000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0235 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 100000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 11 of 11 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |